![Edward Woenker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Edward Woenker active positions
Companies | Position | Start | End |
---|---|---|---|
Novilytic LLC
![]() Novilytic LLC Medical/Nursing ServicesHealth Services Novilytic LLC is a private company that focuses on the pharmaceutical bioreactor market. The company supply kits that enable molecular recognition and quantification, which were developed and validated in collaboration with pharmaceutical pilot partners and customers. The company is based in West Lafayette, IN. Novilytic has worked on a number of SBIR grants through the National Institute of Health and its associated institutes. The company is backed by more than 10 patents (and two pending), partnerships with multiple analytical instrument companies, 2 pharmaceutical consortiums, and analytical science universities. The company's technology helps ensure quality and consistency by recognizing molecular structure early and often, which saves time and reduces purification costs. The CEO of the company is Paul C. Dreier. | Director/Board Member | - | - |
Career history of Edward Woenker
Statistics
International
United States | 2 |
Operational
Director/Board Member | 1 |
Sectoral
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Novilytic LLC
![]() Novilytic LLC Medical/Nursing ServicesHealth Services Novilytic LLC is a private company that focuses on the pharmaceutical bioreactor market. The company supply kits that enable molecular recognition and quantification, which were developed and validated in collaboration with pharmaceutical pilot partners and customers. The company is based in West Lafayette, IN. Novilytic has worked on a number of SBIR grants through the National Institute of Health and its associated institutes. The company is backed by more than 10 patents (and two pending), partnerships with multiple analytical instrument companies, 2 pharmaceutical consortiums, and analytical science universities. The company's technology helps ensure quality and consistency by recognizing molecular structure early and often, which saves time and reduces purification costs. The CEO of the company is Paul C. Dreier. | Health Services |
- Stock Market
- Insiders
- Edward Woenker
- Experience